Providing Quality HIV Care

Arriving on the one-year anniversary of nationwide COVID-19 shutdowns, the 2021 Conference on Retroviruses and Opportunistic Infections won't be in person this year—but it will emphasize COVID-19 alongside important HIV prevention and treatment updates.

March 4, 2021: Improving care for PLWH in transition from incarceration; long-acting PrEP's potential in Black and Latinx communities; comorbidity rates and COVID-19 risk among PLWH; how COVID lockdowns affect the HIV epidemic.

Beyond the big-picture improvements, a closer look at the data reveals stark racial and geographic disparities in HIV incidence and prevalence.

The worst fears about HIV and COVID-19 don’t appear to have materialized, but concerns persist, particularly in cases where HIV treatment efficacy is suboptimal or comorbidities are present.

A new study shows that almost two-thirds of older adults who were diagnosed with HIV at a Connecticut clinic were already at an advanced stage of disease progression.

Two studies out of Europe aimed to give data on which patients with HIV benefit most from lipid-lowering medications, but they both ultimately concluded that better CVD risk-assessment tools—targeted specifically for PLWH—are needed.

Feb. 25, 2021: High HCV SVR among people using substances; geographic HIV care disparities among Black Americans; self-administered imiquimod vs. ASIL excision; PrEP uptake in syringe service programs.

Racial and generational equity demand that leaders with “founder’s syndrome” transfer knowledge, relationships, and connections to new leaders in the movement to end HIV.

Raniyah Copeland and Stephaun Wallace explain the mission and context for the Black AIDS Institute’s new Scientific Advisory Committee.

The findings add to evidence that injectable PrEP could ultimately have greater real-world efficacy than daily oral PrEP in many populations, thanks to better adherence.